CONTINUE TO SITE ➞

Don't miss tomorrow's biopharma industry news

Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.

Daily Dive M-F

Commercialization Weekly Every Wednesday

Gene Therapy Weekly Every Thursday

Emerging Biotech Weekly Every Tuesday

By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Deep Dive
Library
Events
Press Releases

Pharma
Biotech
FDA
Clinical Trials
Deals
Drug Pricing
Gene Therapy

What We're Reading: Page 347

Industry reads hand-picked by our editors

Mar 07, 2016

Wall Street Journal
Valeant Expects to Report Results, Update Guidance Next Week
Reuters
Europe launches new fast approval scheme for promising drugs
Stat
Jimmy Carter says he no longer needs cancer treatment
LA Times
UCLA will get hundreds of millions for rights to prostate cancer drug

Mar 04, 2016

Bloomberg
Sanofi's Eyes May Be Bigger Than its Budget
Stat
The newest cancer therapies don’t work on everyone. Now, doctors have a clue why
MIT Technology Review
Genetically engineered immune cells are saving the lives of cancer patients. That may be just the start.

Mar 03, 2016

Bloomberg
New York Said to Investigate Insurers Over Hepatitis C Drugs
The Street
Biomarin Drug Provides 'Substantial Benefit' to Kids with Rare, Fatal Brain Disease
Wall Street Journal
Battling Infectious Diseases in the 20th Century: The Impact of Vaccines

Mar 02, 2016

Wall Street Journal
The Human Body, According to Venture Capitalists
Reuters
New FDA guidelines aim to prevent Zika transmission via tissue, cell donation
Stat
Leading Alzheimer’s group splinters over claims of misplaced priorities and lavish spending

Mar 01, 2016

NY Times
Waste in Cancer Drugs Costs $3 Billion a Year, a Study Says
Bloomberg
BioMarin's Hunt for Break-Even
Reuters
Scientists find Zika increases risk of rare neurological illness
The Atlantic
Viruses Have Their Own Version of CRISPR

Feb 29, 2016

Reuters
Closely watched AstraZeneca cancer drug fails in mesothelioma
Bloomberg
His Job Is to Sell a $1,000 Pill for $10 Without Losing Money
Stat
Doctors promoting treatments on social media routinely fail to disclose ties to drug makers
FierceBiotech
With ataluren under a cloud, PTC plunges (again) after a market setback in Germany

Feb 26, 2016

Stat
On precision medicine, Obama is playing the long game
Reuters
Old red dye shows promise as new cancer foe
Economic Times
Lupin to invest in Japan; eyes 20 launches
Cardio Biref
At the FDA Rob Califf Will Champion Clinical Trials

Previous Next

Get the free newsletter

Subscribe to BioPharma Dive for top news, trends & analysis

Email:

Select Newsletter: Daily Dive M-F
Select Newsletter: Commercialization Weekly Every Wednesday
Select Newsletter: Gene Therapy Weekly Every Thursday
Select Newsletter: Emerging Biotech Weekly Every Tuesday
Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

A valid email address is required. Please select at least one newsletter.

Library resources

Trendline
Inside the world of cell therapies Supported by ProBio CDMO
Trendline
Inside the market strategies of today’s drugmakers Supported by Evaluate
Trendline
The latest developments on the gene therapy frontier Supported by Mirus Bio LLC

View all

Company Announcements

View all | Post a press release

Events

View all | Promote an event

Industry Intel

2026 Life Sciences AI & Data Predictions Webinar - on demand • Provided by Snowflake
Revolutionizing Next Generation Gene Therapies with On-Demand Large DNA Construct Synthesis and Novel, Designable Delivery Vehicles Webinar - on demand • Provided by Ansa Biotechnologies
Top Ways that AI Will Change Life Sciences Webinar - on demand • Provided by Salesforce

Explore

About
Editorial Team
Contact Us
Newsletter
Purchase Licensing Rights
Press Releases
What We're Reading

Reach our audience

Advertising
Post a press release
Promote an event

Related Publications

Healthcare Dive
MedTech Dive

Industry Dive is an Informa TechTarget business.

This website is owned and operated by Informa TechTarget, part of a global network that informs, influences and connects the world's technology buyers and sellers. All copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. TechTarget, Inc.'s registered office is 275 Grove St. Newton, MA 02466.

Home
- Pharma
- Biotech
- FDA
- Clinical Trials
- Deals
- Drug Pricing
- Gene Therapy
Deep Dive
Library
Events
Press Releases

Get BioPharma Dive in your inbox

The free newsletter covering the top industry headlines

Email:

Select Newsletter: Daily Dive M-F
Select Newsletter: Commercialization Weekly Every Wednesday
Select Newsletter: Gene Therapy Weekly Every Thursday
Select Newsletter: Emerging Biotech Weekly Every Tuesday
Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

A valid email address is required. Please select at least one newsletter.